Mark Olsen to Prognosis
This is a "connection" page, showing publications Mark Olsen has written about Prognosis.
Connection Strength
0.021
-
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012 Apr 20; 30(12):1371-7.
Score: 0.021
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.